ArticleThe American journal of surgical pathology2014
Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain.
Article in The American journal of surgical pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
82 citing papers in PubMed, 162 citations in OpenAlex.
- Trial
- Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019Trial
- Is There a Tumor Proportion Score Threshold at Which Tumor-Cell PD-L1 Adds Prognostic Information Beyond the International Prognostic Index in Large B-Cell Lymphoma?Diagnostics (Basel, Switzerland) · 2026Article
- Pediatric lymphomas: overview and diagnostic challenges.Virchows Archiv : an international journal of pathology · 2025Review
- Dedicated diagnostic approaches for mature B-cell non-Hodgkin lymphomas occurring in children, adolescents, and young adults.Histopathology · 2025Review
- A Prognostic Riskscore Model Related toInternational journal of genomics · 2025Article
- Evaluation of immune checkpoint inhibitor efficacy for solid tumors withJournal for immunotherapy of cancer · 2024Article
- Circulating tumor DNA assisting lymphoma genetic feature profiling and identification.Annals of hematology · 2024Article
- Review
- Programmed Death Ligand 1 (PD-L1) Expression in Lymphomas: State of the Art.International journal of molecular sciences · 2024Review
- Pembrolizumab With R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy, and Safety With Long-Term Follow-Up.Clinical lymphoma, myeloma & leukemia · 2024Article
- High PDL1/PDL2 gene expression correlates with worse outcome in primary mediastinal large B-cell lymphoma.Blood advances · 2023Article
- Mediastinal large B cell lymphoma and surrounding gray areas: a report of the lymphoma workshop of the 20th meeting of the European Association for Haematopathology.Virchows Archiv : an international journal of pathology · 2023Review
- Review
- Efficacy of Immune Checkpoint Blockade and Biomarkers of Response in Lymphoma: A Narrative Review.Biomedicines · 2023Review
- Assessment of Response to Immunotherapy in Patients with Hodgkin Lymphoma: Towards Quantifying Changes in Tumor Burden Using FDG-PET/CT.Journal of clinical medicine · 2023Review
- Review
- Novel strategies for cancer immunotherapy: counter-immunoediting therapy.Journal of hematology & oncology · 2023Review
- Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma.BMC cancer · 2022Article
- PD-1/PD-L1 Pathway: A Therapeutic Target in CD30+ Large Cell Lymphomas.Biomedicines · 2022Review
22 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
Abstract
Primary mediastinal (thymic) large B-cell lymphoma (PMBL) and diffuse large B-cell lymphoma (DLBCL) are tumors with distinct clinical and molecular characteristics that are difficult to distinguish by histopathologic and phenotypic analyses alone. Programmed cell death 1 ligand 2 (PD-L2) is a cell surface protein expressed by activated macrophages and dendritic cells that binds PD-1 on T cells to inhibit immune responses. Amplification and/or translocations involving chromosome 9p24.1, a region that includes PDCD1LG2-encoding PD-L2, is a common event in PMBL but not DLBCL and suggests that PD-L2 expression might be a distinguishing feature of PMBL. We developed an assay for the immunohistochemical detection of PD-L2 protein in fixed biopsy specimens (PD-L2 IHC), which we applied to a cohort of PMBLs and DLBCLs. For a subset of cases, we correlated the results of PD-L2 IHC with PDCD1LG2 copy number (CN) as determined by quantitative polymerase chain reaction. Twenty-three of 32 (72%) PMBLs but only 1 of 37 (3%) DLBCLs were positive by PD-L2 IHC. Among PMBLs with PDCD1LG2 CN gain, all were positive by PD-L2 IHC. One PMBL without CN gain was positive by PD-L2 IHC. When expressed in PMBL, PD-L2 was restricted to tumor cells and not detected on intratumoral macrophages. We conclude that PD-L2 protein is robustly expressed by the majority of PMBLs but only rare DLBCLs and often associated with PDCD1LG2 copy gain. PD-L2 IHC may serve as a useful ancillary test for distinguishing PMBL from DLBCL and for the rational selection of patients for therapeutic antibodies that inhibit PD-1 signaling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.